Compare Stocks: ENLV, YARW, DTSQ, and KLRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTSQ DT Cloud Star Acquisition	$11.34	$11.33	$10.45 ▼ $12.90	$100.93M	-0.01	805 shs	14 shs
ENLV Enlivex Therapeutics	$1.35	$4.41	$1.35 ▼ $27.15	$23.61M	1.6	290,211 shs	531,296 shs
KLRS Kalaris Therapeutics	$4.03	$4.17	$3.03 ▼ $11.88	$95.95M	0.2	58,984 shs	52,614 shs
YARW Yarrow Bioscience	$37.00	$0.00	$14.02 ▼ $46.95	$98.79M	1.95	31,085 shs	39,377 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTSQ DT Cloud Star Acquisition	0.00%	-0.53%	+0.04%	+0.49%	+8.52%
ENLV Enlivex Therapeutics	0.00%	-8.16%	-35.41%	-89.58%	-91.43%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%
YARW Yarrow Bioscience	0.00%	+1.59%	+5.65%	+3,699,999,900.00%	+3,699,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTSQ DT Cloud Star Acquisition	$11.34	$11.33	$10.45 ▼ $12.90	$100.93M	-0.01	805 shs	14 shs
ENLV Enlivex Therapeutics	$1.35	$4.41	$1.35 ▼ $27.15	$23.61M	1.6	290,211 shs	531,296 shs
KLRS Kalaris Therapeutics	$4.03	$4.17	$3.03 ▼ $11.88	$95.95M	0.2	58,984 shs	52,614 shs
YARW Yarrow Bioscience	$37.00	$0.00	$14.02 ▼ $46.95	$98.79M	1.95	31,085 shs	39,377 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTSQ DT Cloud Star Acquisition	0.00%	-0.53%	+0.04%	+0.49%	+8.52%
ENLV Enlivex Therapeutics	0.00%	-8.16%	-35.41%	-89.58%	-91.43%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%
YARW Yarrow Bioscience	0.00%	+1.59%	+5.65%	+3,699,999,900.00%	+3,699,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	18,233.33% Upside
KLRS Kalaris Therapeutics	2.88	Moderate Buy	$18.75	365.26% Upside
YARW Yarrow Bioscience	3.00	Buy	$58.00	56.76% Upside

Current Analyst Ratings Breakdown

Latest ENLV, YARW, DTSQ, and KLRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	YARW Yarrow Bioscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$58.00
7/28/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	YARW Yarrow Bioscience	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/7/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/23/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	KLRS Kalaris Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/9/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$4.21 per share	N/A
YARW Yarrow Bioscience	$570K	173.32	N/A	N/A	$41.71 per share	0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	9/4/2026 (Estimated)
KLRS Kalaris Therapeutics	-$43.44M	-$2.02	N/A	N/A	N/A	N/A	-71.71%	-42.95%	N/A
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest ENLV, YARW, DTSQ, and KLRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	KLRS Kalaris Therapeutics	-$0.50	-$0.48	+$0.02	-$0.48	N/A	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	193.24	193.24
KLRS Kalaris Therapeutics	N/A	10.98	10.98
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTSQ DT Cloud Star Acquisition	N/A
ENLV Enlivex Therapeutics	1.02%
KLRS Kalaris Therapeutics	66.05%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
DTSQ DT Cloud Star Acquisition	52.88%
ENLV Enlivex Therapeutics	12.28%
KLRS Kalaris Therapeutics	68.10%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A
ENLV Enlivex Therapeutics	70	17.49 million	15.34 million	Optionable
KLRS Kalaris Therapeutics	110	23.81 million	7.59 million	N/A
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

ENLV, YARW, DTSQ, and KLRS Headlines

Recent News About These Companies

Wall Street Zen Upgrades Yarrow Bioscience (NASDAQ:YARW) to "Hold"

August 22, 2026 | americanbankingnews.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, YARW, DTSQ, and KLRS Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.34 0.00 (0.00%)

Closing price 08/28/2026

Extended Trading

$11.36 +0.02 (+0.13%)

As of 03:59 AM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

Enlivex Therapeutics NASDAQ:ENLV

$1.35 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.01 (+0.74%)

As of 07:26 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Kalaris Therapeutics NASDAQ:KLRS

$4.03 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$4.04 +0.00 (+0.12%)

As of 03:59 AM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Yarrow Bioscience NASDAQ:YARW

$37.00 0.00 (0.00%)

Closing price 08/28/2026 03:59 PM Eastern

Extended Trading

$40.08 +3.08 (+8.32%)

As of 07:28 AM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, YARW, DTSQ, and KLRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, YARW, DTSQ, and KLRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, YARW, DTSQ, and KLRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, YARW, DTSQ, and KLRS Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

Enlivex Therapeutics NASDAQ:ENLV

Kalaris Therapeutics NASDAQ:KLRS

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, YARW, DTSQ, and KLRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, YARW, DTSQ, and KLRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, YARW, DTSQ, and KLRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, YARW, DTSQ, and KLRS Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

Enlivex Therapeutics NASDAQ:ENLV

Kalaris Therapeutics NASDAQ:KLRS

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools